title: Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.
abstract: A meta-analysis was conducted to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications. We searched PUBMED, EMBASE and the Cochrane Library through June 2016 to identify randomized controlled trials of bevacizumab and wound-healing complications. Seven RCTs studies involving 5,147 participants were included in the analysis. Compared with routine therapy, bevacizumab increased the incidence of wound-healing complications for various cancers. The pooled estimate of odds ratio (OR) was 2.32, and the 95 % confidence intervals (CI) was 1.43 to 3.75. (P < 0.001). Subgroup analyses revealed the similar result in colon carcinoma patients. In conclusion, bevacizumab increases the incidence of wound-healing complications for cancers especially for colon neoplasms patients. However, the adverse effect is not appeared in breast cancer, metastatic renal cell carcinoma, non-small-cell lung cancer and gastro-oesophageal adenocarcinoma. Due to the findings relying chiefly on data from single or two studies, hence, further research is required to assess the wound-healing complications risk of bevacizumab in each oncological indication.
authors.affiliation: Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
authors.forename: Hongliang
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
authors.forename: Zhenguang
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
authors.forename: Xiaoqin
authors.initials: X
authors.lastname: Zou
authors.affiliation: Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
authors.forename: Taotao
authors.initials: T
authors.lastname: Liu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000068258:Bevacizumab / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D006801:Humans; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: bevacizumab; meta-analysis; systematic review; wound-healing complications